IFNB1 and myeloid sarcoma: Whereas a type I IFN signature in lupus is associated with active disease [31], it correlates with an alleviation of symptoms in multiple sclerosis (MS) [32], and IFNβ therapy has been used successfully to treat patients with MS [33].